The IDIBAPS research institute has worldwide renowned expertise inbiomedical research and offers the highest quality platforms to ensure the best quality of BLB services.
Gilead Sciences, Inc. is a
biopharmaceutical company that discovers, develops and commercializes innovative medicines for patients living with life-threatening diseases. Gilead trusts a significant part of its pre-clinical research in liver diseases to BLB, this partnership enhances Gilead’s ability to develop new treatments for aCLD as efficiently as possible.
GAT Therapeutics is an early stage
biopharma targeting fibrosis and age-related diseases. BLB develops the pre-clinical research of GATTx characterizing the effects of its leading drug candidate GTX-011 for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).
GAT Therapeuthics
BLB was selected to be part of the 2nd edition of this entrepreneurship program organized by Caixa Capital Risk and La Caixa Foundation. The program helped and fully supported the generation and development of BLB.
Brudylab is a nutraceutical company specialized in medical supplementation based on the health benefits of docosahexaenoic acid (DHA). BLB supports the pre-clinical research & clinical development of BrudyLab’s DHA to treat chronic liver disease.
Inventiva is a clinical stage
biopharmaceutical with expertise in fibrosis, oncology and orphan diseases. BLB develops pre-clinical research to ascertain the effects and underlying mechanisms of Inventiva’s lead compound lanifibranor as therapeutic for chronic liver disease and portal hypertension.
Conatus is a biotechnology company aimed at developing and commercializing novel medicines to treat liver disease. BLB conducted important preclinical research into the mechanism of Conatus’ lead compound emricasan in the field of liver cirrhosis & portal hypertension.
Surrozen is a biotech company developing innovative regenerative antibodies to repair tissues and organs damaged by serious diseases. BLB provides cutting-edge research services to enhance the characterization of regenerative pathways in chronic liver disease.

BLB partners with Novo Nordisk, a global healthcare company, to understand the effects of novel chemical entities for the treatment of chronic liver disease and portal hypertension.
Novo Nordisk

The complete pre-clinical Solution

BLB works toward helping our partners to accelerate the development of new chemical entities to treat human liver disease. We value talent, experience and dedication of each of our employees.

BLB seeks outstanding scientists, pharmacologists, biomedical engineers, computational biologists and business developers